乳腺浸润性导管癌中CD44、TRIM24、TAGLN-2、ER、PR的表达及其临床意义

摘要

Purpose To study the expression of biomolecules of PI3K-AKT signaling pathway including CD44,TRIM24,TAGLN-2,ER and PR in breast invasive ductal carcinoma,and to explore their clinicopathologic significance.Methods The expression of CD44,TRIM24,TAGLN-2,ER and PR in 73 cases of breast invasive ductal carcinoma were detected by immunohistochemist~ (IHC) technology.And the relationship between the expression of these biomarkers and the age of patients,tumor size,histological grade,lymph node metastasis was analyzed.Besides,the influence of these biomarkers on prognosis and the relationship between the expression of these biomarkers were also analyzed.Results There was no significant relationship between the expression of these biomarkers and the age of patients,tumor size,histological grade,lymph node metastasis.CD44 expression was positively conelated with TAGLN-2 expression (r =0.311,P =0.007),TRIM24 expression was positively correlated with TAGLN-2 expression (r =0.421,P =0.000).CD44 expression was negatively correlated with ER expression (r =-0.285,P =0.015).ER expression was positively correlated with PR expression (r =0.598,P =0.000).The postoperative 5-year cumulative survival-rate of CD44 positive group was lower than those of CD44 negative group (P =0.002),in contrast,the postoperative 5-year survival rate of ER positive group was higher than those of ER negative group (P =0.026).Conclusion Through PI3K-AKT signaling pathway,CD44 and TRIM24 may up-regulate TAGLN-2 expression,however,CD44 may down-regulate ER and PR expression.CD44 and ER may act an useful predictor for the prognosis of breast invasive ductal carcinoma.Combined detection of CD44,ER and PR may provide additional therapeutic information which may be useful in breast cancer treatment.%目的 探讨PI3K-AKT信号通路分子CD44、TRIM24、TAGLN-2、ER、PR在乳腺浸润性导管癌中的表达及其临床意义.方法 应用免疫组化EnVision两步法检测73例乳腺浸润性导管癌组织中CD44、TRIM24、TAGLN-2、ER、PR的表达,分析其与临床病理特征的关系及表达的相关性.结果 CD44、TRIM24、TAGLN-2、ER、PR的表达与患者年龄、肿瘤大小、组织学分级及淋巴结转移无明显相关性.CD44与TAGLN-2表达呈正相关(r=0.311,P=0.007);TRIM24与TAGLN-2表达呈正相关(r=0.421,P =0.000);CD44与ER表达呈负相关(r=-0.285,P=0.015);ER与PR表达呈正相关(r=0.598,P=0.000).CD44阳性组患者术后5年累积生存率低于CD44阴性组(P =0.002);ER阳性组患者术后5年累积生存率高于ER阴性组(P=0.026).结论 在乳腺癌中CD44、TRIM24可能通过激活PI3K-AKT信号通路上调TAGLN-2表达,CD44可能通过激活PI3K-AKT信号通路下调ER表达.CD44、ER有望成为预测乳腺浸润性导管癌患者预后的辅助因子,联合检测CD44、ER、PR的表达有助于乳腺浸润性导管癌治疗策略的选择及优化.